Multiple-system atrophy is an orphan disease (Orpha number, ORPHA102 [www.orpha.net]).The estimated mean incidence is 0.6 to 0.7 cases per 100,000 person-years, with a range of 0.1 to 2.4 cases ...

--Theravance Biopharma, Inc. today announced that the US Food and Drug Administration has granted Orphan Drug Designation status to ampreloxetine for the treatment of symptomatic neurogenic ...

Multiple system atrophy — whose worldwide awareness day is commemorated every Oct. 3 — includes disorders that historically had been referred to as Shy-Drager syndrome, olivopontocerebellar ...

DUBLIN, May 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted ...

Multiple system atrophy (MSA) refers to a group of progressive neurodegenerative disorders that affects the basal ganglia and the motor system (parkinsonism), autonomic nervous system (dysautonomia ...

The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol ...

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting ...

Bhattacharya, K, Saadia, D, Eisenkraft, B, et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002;59:835-842 Crossref ...

DUBLIN, May 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted ...

Neurogenic bladder is caused by damage to the nerves that allow you to control the timing of urination. Treatments for ...